Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model
| Autor: | Zhuoyi Hu, Jinshu Xu, Jie Wu, Liu Wentao, Dongya Zhu, Yin Zhang, Zheng Zhu, Jingjing Liu, Rouel S. Roque, Xiangchun Shen |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Time Factors Chaperonins medicine.medical_treatment Gonadotropin-releasing hormone Lymphocyte Activation Cancer Vaccines Gonadotropin-Releasing Hormone Interferon-gamma Mice Viral Proteins Prostate cancer Immune system Bacterial Proteins Cell Line Tumor Heat shock protein Internal medicine medicine Animals Testosterone Lymphocytes Cell Proliferation Immunity Cellular Vaccines Synthetic Vaccines Conjugate biology Prostatic Neoplasms Chaperonin 60 Neoplasms Experimental Immunotherapy Luteinizing Hormone medicine.disease Recombinant Proteins Mice Inbred C57BL Endocrinology Oncology Immunoglobulin G Antibody Formation Cancer research biology.protein Antibody Luteinizing hormone |
| Zdroj: | Cancer Letters. 259:240-250 |
| ISSN: | 0304-3835 |
| Popis: | We have previously shown that anti-GnRH antibodies responses can be induced by synthetic GnRH3-hinge-MVP peptide. In this study, GnRH3-hinge-MVP of conjugation to heat shock protein 65 was used as an adjuvant-free vaccine to assess the therapeutic effects of GnRH immunoneutralisation on tumor development in the mice model. Compared with mice treated with Hsp65 and PBS, mice of the o.t. model receiving in situ treatment GnRH3-hinge-MVP-Hsp65 had significant prolongation of survival and suppression of local tumor growth. Serum levels of both testosterone and luteinizing hormone were reduced by treatment with GnRH3-hinge-MVP-Hsp65 (p < 0.05). Further analyses of cell mediated immune responses showed that GnRH3-hinge-MVP-Hsp65 induced stronger lymphocyte proliferative responses and higher levels of IFN-γ (p < 0.001). The conjugation of the recombinant GnRH peptide to Hsp65 could be considered a promising approach for the development of an efficacious vaccine against the prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect